

CMS MedCAC, March 24, 2015

“Molecular Pathology Testing to Estimate Prognosis in Cancer”

Robert Bilkovski, MD, MBA

Disclosures



Robert Bilkovski, MD, MBA, is employed by Abbott Molecular as the Senior Associate Medical Director of Medical, Regulatory and Clinical Affairs. Therefore, his financial interest is greater than \$10,000.

ALK Translocation Test

(e.g. Abbott Molecular ALK-VYSIS test)

Data <u>Excluded</u> From Review	Linkage to Clinical Benefit (Y/N)	Data <u>Included</u> For Review
<ul style="list-style-type: none"> FDA labeling based on randomized controlled trial 	YES	
<ul style="list-style-type: none"> <u>Efficacy</u> in patient care of therapies indicated by the test 	YES	<ul style="list-style-type: none"> Almost no “prognostic” data exists
<ul style="list-style-type: none"> National and international guidelines for using ALK translocation tests to select patients for crizotinib therapy 	YES	